The new third board of vesicle anticancer medicine enterprises

[China Pharmaceutical network enterprise news] on March 1, Hubei shengqi'an Biotechnology Co., Ltd (hereinafter referred to as "shengqi'an") was listed in the national small and medium-sized enterprise share transfer system It is understood that the second project independently developed by the company, tumor vesicle treatment for obstructive cholangiocarcinoma, has also obtained the clinical application ethics approval document of Tianjin Nankai hospital, and the relevant price declaration procedures are being handled Shengqi'an company expects that the two projects will gradually enter clinical application in the first half of this year Shengqi'an is also the company that the bubble anti-cancer drug company landed on the new third board (picture source: Baidu picture) According to the company's public transfer instructions, from the results of previous clinical research and treatment of cancer hydrothorax subjects, from February 2012 to September 2015, 36 patients with different types of cancer hydrothorax were experimentally treated in the company's cooperation hospital The results showed that the total effective rate of tumor vesicle technology for the treatment of cancer hydrothorax and ascites was 72.22%, and the total effective rate for the treatment of lung cancer hydrothorax was 77.78% At present, the technology has been approved by the hospital's clinical application ethics, and the relevant price declaration procedures are in process In addition to the above two projects, at present, in the treatment of solid tumors such as lung cancer, liver cancer, gastric cancer, breast cancer, cervical cancer and leukemia, the company has completed relevant in vitro and animal tests, completed the pre clinical layout, and will gradually start clinical application transformation In the future, in addition to cancer prevention and control technology, the company will also develop new anti-tumor drugs and cancer prevention and control vaccines IMS Health pointed out in the global cancer trend report that in the past five years, the annual compound growth rate of the global cancer drug market was 7.4% In 2015, the global total cost of cancer treatment and adjuvant treatment was $107 billion, up 11.5% year on year It is predicted that in the next five years, the cancer drug market will maintain this upward trend By 2020, the global cancer drug market will reach 150 billion US dollars China is also seizing the blue ocean market of cancer drugs From policy encouragement to capital intervention, domestic enterprises engaged in research and development of cancer drugs are increasing year by year It is understood that in 2015, the number of Chinese chemical 1.1 drugs declared was more than three times that of 2010 The focus of research and development is in the field of anti-tumor From 2010 to 2015, there were 105 anti-tumor directions in the research of Chinese 1.1 drugs, and the number of them far exceeded the second anti infectious diseases From 2010 to 2015, 7 varieties of innovative drugs were launched in China, including 4 anti-tumor drugs Because of this, all kinds of capital are optimistic about the field of biopharmaceutical with R & D strength According to the statistics of the new third board Research Institute, among the listed companies in the new third board biomedical industry, 28 are mainly engaged in the research and development of pharmaceuticals using biotechnology, with a total market value of about 24.194 billion yuan, including 5 companies with a market value of more than 1 billion yuan, accounting for more than 70% of the total market value of the industry According to the public transfer specification of shengqi'an company, the company has established a complete set of technical barriers and intellectual property protection system At present, it has applied for 13 national inventions, 5 international inventions, 4 national invention authorizations, 1 Hong Kong Invention authorization, 1 American invention authorization, and 1 European invention authorization "At present, there is no other domestic or international peer engaged in such technology research and development In the industry, we are ahead, and in the future, our development direction is to transform the research and clinical application of vesicles into a discipline, so that people are no longer afraid of cancer " The company's relevant person in charge said.